Apple Inc vs Illumina, Inc. — how do they compare? Apple Inc trades at $304.83 (market cap $4.45T), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Apple Inc is far larger — about 152.8× Illumina, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | ILMN | |
|---|---|---|
Market Cap | $4.45T | $29.12B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $205.10 |
52-Week Low | $224.90 | $91.00 |
Enterprise Value | $4.47T | $30.48B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.
Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →